No Data
No Data
Qualigen Therapeutics Signs MoU To Acquire Marizyme, Stock Down In Pre-Market
Qualigen Enters $10B Coronary Artery Bypass Graft Market With Non-Binding MOU To Acquire Marizyme
Express News | Qualigen Seeks to Enter the $10 Billion Cabg Market With Non-Binding Mou to Acquire Marizyme
Qualigen Seeks To Enter The $10 Billion CABG Market With Non-binding MOU To Acquire Marizyme >QLGN
Qualigen to Participate in Next Funding Round for NanoSynex
12 Health Care Stocks Moving In Tuesday's Pre-Market Session